Ray-Coquard, Isabelle;Pautier, Patricia;Pignata, Sandro;Pérol, David;González-Martín, Antonio;Berger, Regina;Fujiwara, Keiichi;Vergote, Ignace;Colombo, Nicoletta;Mäenpää, Johanna;Selle, Frédéric;Sehouli, Jalid;Lorusso, Domenica;Guerra Alía, Eva M;Reinthaller, Alexander;Nagao, Shoji;Lefeuvre-Plesse, Claudia;Canzler, Ulrich;Scambia, Giovanni;Lortholary, Alain;Marmé, Frederik;Combe, Pierre;de Gregorio, Nikolaus;Rodrigues, Manuel;Buderath, Paul;Dubot, Coraline;Burges, Alexander;You, Benoît;Pujade-Lauraine, Eric;Harter, Philipp
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med
2019
381
25
2416-2428

Garcia-Etienne, Carlos A;Mansel, Robert E;Tomatis, Mariano;Heil, Joerg;Biganzoli, Laura;Ferrari, Alberta;Marotti, Lorenza;Sgarella, Adele;Ponti, Antonio
Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice.
Breast
2019
45
89-96

Fasching, P. A.;Quek, R. G. W.;Bhattacharyya, H.;Hurvitz, S. A.;Rugo, H. S.;Ettl, J.
Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial
Ann Oncol
2019
30 Suppl 3

Brunet, T.;Konrad, S.;Kiechle, M.;Meindl, A.;Ramser, J.;Gross, E.
Identification of therapy-relevant "BRCAness"-associated candidate genes in ovarian cancer
Eur J Hum Genet
2019
27 Suppl 1
554-554

Ettl, J.;Quek, R. G. W.;Bhattacharyya, H.;Rugo, H. S.;Hurvitz, S. A.;Goncalves, A.
Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/without visceral disease
Ann Oncol
2019
30 Suppl 5
129-+

Ettl, J.;Quek, R. G. W.;Hurvitz, S. A.;Goncalves, A.;Tudor, I. C.;Rugo, H. S.
Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA
Ann Oncol
2019
30 Suppl 3

Enzensberger, Christian;Rostock, Laura;Graupner, Oliver;Götte, Malena;Wolter, Aline;Vorisek, Carina;Herrmann, Johannes;Axt-Fliedner, Roland
Wall motion tracking in fetal echocardiography-Application of low and high frame rates for strain analysis.
Echocardiography
2019
36
2
386-393

Goettig, Peter;Brandstetter, Hans;Magdolen, Viktor
Surface loops of trypsin-like serine proteases as determinants of function.
Biochimie
2019
166
52-76

Silva, Lakmali Munasinghage;Kryza, Thomas;Stoll, Thomas;Hoogland, Christine;Dong, Ying;Stephens, Carson Ryan;Hastie, Marcus Lachlan;Magdolen, Viktor;Kleifeld, Oded;Gorman, Jeffrey John;Clements, Judith Ann
Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.
Mol Cell Proteomics
2019
18
5
818-836

Fasching, Peter A;Hartkopf, Andreas D;Gass, Paul;Häberle, Lothar;Akpolat-Basci, Leyla;Hein, Alexander;Volz, Bernhard;Taran, Florin-Andrei;Nabieva, Naiba;Pott, Birgit;Overkamp, Friedrich;Einarson, Hanna;Hadji, Peyman;Tesch, Hans;Ettl, Johannes;Lüftner, Diana;Wallwiener, Markus;Müller, Volkmar;Janni, Wolfgang;Fehm, Tanja N;Schneeweiss, Andreas;Untch, Michael;Pott, Dirk;Lux, Michael P;Geyer, Thomas;Liedtke, Cornelia;Seeger, Harald;Wetzig, Sarah;Hartmann, Arndt;Schulz-Wendtland, Rüdiger;Belleville, Erik;Wallwiener, Diethelm;Beckmann, Matthias W;Brucker, Sara Y;Kolberg, Hans-Christian
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Breast Cancer Res Treat
2019
173
2
319-328